Glaucoma and aging

Current Aging Science

Volumn 4, Issue 2, 2011, Pages 110-117

  Guedes, Guilherme ^a,b   Tsai, James C ^a   Loewen, Nils A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hospital de Olhos do Paraná   (Brazil)

Author keywords

Blindness; Glaucoma; Optic nerve degeneration; Outflow

Indexed keywords

AMYLOID BETA PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AGING; ARTICLE; AUTOIMMUNITY; BIOMECHANICS; BLINDNESS; CLOSED ANGLE GLAUCOMA; EXCITOTOXICITY; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MITOCHONDRION; NEUROPROTECTION; OPTIC NERVE; OPTIC NERVE DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA GANGLION CELL; RISK FACTOR; SENESCENCE; VISION; VISUAL ACUITY; VISUAL FIELD;

EID: 79954535342     PISSN: 18746098     EISSN: 18746128     Source Type: Journal    
DOI: 10.2174/1874609811104020110     Document Type: Article

References (137)

1. Nickells RW, Schlamp CL, Li Y, Kaufman PL, Heatley G, Peterson JC, et al. Surgical lowering of elevated intraocular pressure in monkeys prevents progression of glaucomatous disease. Exp Eye Res 2007; 84(4): 729-36.
2. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121(1): 48-56.
3. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120(6): 701-13.
4. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991; 109(8): 1090-5.
5. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120(10): 1268-79.
6. Medeiros FA, Weinreb RN, Sample PA, Gomi CF, Bowd C, Crowston JG, et al. Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma. Arch Ophthalmol 2005; 123(10): 1351-60.
7. Gordon MO, Torri V, Miglior S, Beiser JA, Floriani I, Miller JP, et al. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007; 114(1): 10-9.
8. Meyerhof M. Alî at-Tabarî's "Paradise of Wisdom", one of the oldest Arabic Compendiums of Medicine Isis 1931; 16(1): 6-54.
9. Quigley HA. The number of people with glaucoma worldwide in 2010 and 2020 Br J Ophthalmol 2010; 90(3): 262-267.
10. Bramley T, Peeples P, Walt JG, Juhasz M, Hansen JE. Impact of vision loss on costs and outcomes in medicare beneficiaries with glaucoma. Arch Ophthalmol 2008; 126(6): 849-56.
11. Colón-Emeric CS, Biggs DP, Schenck AP, Lyles KW. Risk factors for hip fracture in skilled nursing facilities: who should be evaluated? Osteoporos Int 2003; 14(6): 484-9.
12. Foster PJ. The epidemiology of primary angle closure and associated glaucomatous optic neuropathy. Semin Ophthalmol 2002; 17(2): 50-8.
13. Congdon NG, Youlin Q, Quigley H, Hung PT, Wang TH, Ho TC, et al. Biometry and primary angle-closure glaucoma among Chinese, white, and black populations. Ophthalmology 1997; 104(9): 1489-95.
14. Damji KF, Allingham RR, Moroi SE, Shields MB, Shafranov G. Shields' Textbook of Glaucoma. Fifth Edition. Philadelphia: Lippincott Williams & Wilkins 2004.
15. Foster PJ, Oen FT, Machin D, Ng TP, Devereux JG, Johnson GJ, et al. The prevalence of glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district. Arch Ophthalmol 2000; 118(8): 1105-11.
16. Dandona L, Dandona R, Mandal P, Srinivas M, John RK, McCarty CA, et al. Angle-closure glaucoma in an urban population in southern India. The Andhra Pradesh eye disease study. Ophthalmology 2000; 107(9): 1710-6.
17. Marchini G, Bonomi L, Marraffa M, Bernardi P, De Franco I, Perfetti S, et al. Epidemiology of angle-closure glaucoma: prevalence, clinical types, and association with peripheral anterior chamber depth in the Egna-Neumarket Glaucoma Study. Ophthalmology 2000; 107(5): 998-1003.
18. Quigley HA. Angle-closure glaucoma-simpler answers to complex mechanisms: LXVI Edward Jackson Memorial Lecture. Am J Ophthalmol 2009; 148(5): 657-669.
19. Alward WL. Medical management of glaucoma. N Engl J Med 1998; 339(18): 1298-307.
20. Grierson I, Lee WR, Abraham S. The effects of topical pilocarpine on the morphology of the outflow apparatus of the baboon (Papio cynocephalus). Invest Ophthalmol Vis Sci 1979; 18(4): 346-55.
21. Bill A, Phillips CI. Uveoscleral drainage of aqueous humour in human eyes. Exp Eye Res 1971; 12(3): 275-81.
22. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Three-year follow-up of the tube versus trabeculectomy study. Am J Ophthalmol 2009; 148(5): 670-84.
23. Rolim de Moura C, Paranhos A, Wormald R. Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst Rev 2007; (4): CD003919.
24. Francis BA, See RF, Rao NA, Minckler DS, Baerveldt G. Aβ interno trabeculectomy: development of a novel device (Trabectome) and surgery for open-angle glaucoma. J Glaucoma 2006; 15(1): 68-73.
25. Edmunds B, Thompson JR, Salmon JF, Wormald RP. The National Survey of Trabeculectomy. III. Early and late complications. Eye 2002; 16(3): 297-303.
26. Medeiros F A, Alencar LM, Zangwill LM, Bowd C, Sample PA, Weinreb RN. Prediction of functional loss in glaucoma from progressive optic disc damage. Arch Ophthalmol 2009; 127(10): 1250-6.
27. Caprioli J, Zeyen T. A critical discussion of the rates of progression and causes of optic nerve damage in glaucoma: international glaucoma think tank II: July 25-26, 2008, Florence, Italy. J Glaucoma 2009; 18(6): 1-21.
28. Hattenhauer MG, Johnson DH, Ing HH, Herman DC, Hodge DO, Yawn BP, et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998; 105(11): 2099-104.
29. Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res 2005; 24(5): 612-37.
30. Toris CB, Yablonski ME, Wang YL, Camras CB. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol 1999; 127(4): 407-12.
31. Bill A. Aqueous humor dynamics in monkeys (Macaca irus and Cercopithecus ethiops). Exp Eye Res 1971; 11(2): 195.
32. Toris CB, Koepsell SA, Yablonski ME, Camras CB. Aqueous humor dynamics in ocular hypertensive patients. J Glaucoma 2002; 11(3): 253-8.
33. Caspari R, Lee SH. Older age becomes common late in human evolution. Proc Natl Acad Sci USA 2004; 101(30): 10895-900.
34. Stein-Streilein J, Streilein JW. Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. Int Rev Immunol 21(2-3): 123-52.
35. Wenkel H, Streilein JW. Analysis of immune deviation elicited by antigens injected into the subretinal space. Invest Ophthalmol Vis Sci 1998; 39(10): 1823-34.
36. Streilein JW. Unraveling immune privilege. Science 1995; 270(5239): 1158-9.
37. Resch ZT, Fautsch MP. Glaucoma-associated myocilin: a better understanding but much more to learn. Exp Eye Res 2009; 88(4): 704-12.
38. Lee ES, Gabelt BT, Faralli JA, Peters DM, Brandt CR, Kaufman PL, et al. COCH transgene expression by adenovirus in cultured human trabecular meshwork cells and its effect on outflow facility in monkey organ cultured anterior segments. Invest Ophthalmol Vis Sci 2010; 51(4): 2060-6.
39. Lindsey JD, Crowston JG, Tran A, Morris C, Weinreb RN. Direct matrix metalloproteinase enhancement of transscleral permeability. Invest Ophthalmol Vis Sci 2007; 48(2): 752-5.
40. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of openangle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996; 103(10): 1661-9.
41. Varma R, Ying-Lai M, Francis BA, Nguyen BB-T, Deneen J, Wilson MR, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004; 111(8): 1439-48.
42. Klein BE, Klein R, Linton KL. Intraocular pressure in an American community. The Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 1992; 33(7): 2224-8.
43. Li Y, Wolf NS. Effects of age and long-term caloric restriction on the aqueous collecting channel in the mouse eye. J Glaucoma 1997; 6(1): 18-22.
44. Wang N, Chintala SK, Fini ME, Schuman JS. Activation of a tissue- specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype. Nat Med 2001; 7(3): 304-9.
45. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999; 107(1): 85-97.
46. Itoh H, Nakao K. Vascular stress response and endothelial vasoactive factors for vascular remodelling. Diabetes Res Clin Pract 1999; 45(2-3): 83-8.
47. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336(15): 1066-71.
48. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NFkappa B transcription factor and HIV-1. EMBO J 1991; 10(8): 2247-58.
49. Yeh LH, Park YJ, Hansalia RJ, Ahmed IS, Deshpande SS, Goldschmidt-Clermont PJ, et al. Shear-induced tyrosine phosphorylation in endothelial cells requires Rac1-dependent production of ROS. Am J Physiol 1999; 276(4 Pt 1): C838-47.
50. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57791-804.
51. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, et al. Advanced glycation end products cause epithelial- myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001; 108(12): 1853-63.
52. Luna C, Li G, Liton PB, Qiu J, Epstein DL, Challa P, et al. Resveratrol prevents the expression of glaucoma markers induced by chronic oxidative stress in trabecular meshwork cells. Food Chem Toxicol 2009; 47(1): 198-204.
53. Holmes-McNary M, Baldwin AS. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 2000; 60(13): 3477-83.
54. Martín AR, Villegas I, Sánchez-Hidalgo M, La Lastra CA de. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Ophthalmol 2006; 147(8): 873-85.
55. Tsai SH, Lin-Shiau SY, Lin JK. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Ophthalmol 1999; 126(3): 673-80.
56. Kubota S, Kurihara T, Mochimaru H, Satofuka S, Noda K, Ozawa Y, et al. Prevention of ocular inflammation in endotoxin-induced uveitis with resveratrol by inhibiting oxidative damage and nuclear factor-kappaB activation. Invest Ophthalmol Vis Sci 2009; 50(7): 3512-9.
57. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127(6): 1109-22.
58. Baur J, Pearson K, Price N, Jamieson H. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444337-342.
59. Howitz K, Bitterman K, Cohen H, DW. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Trends Cell Biol 1999; 425191-196.
60. Valenzano DR, Cellerino A. Resveratrol and the pharmacology of aging: a new vertebrate model to validate an old molecule. Cell Cycle 2006; 5(10): 1027-1032.
61. Valenzano DR, Terzibasi E, Genade T, Cattaneo A, Domenici L, Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 2006; 16(3): 296-300.
62. Bauer J, Goupil S, Garber G, Helfand S. Assay for the identification of lifespan-extending interventions in Drosophila melanogaster Proc Natl Acad Sci USA 2004; 10112980-12985.
63. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5(6): 493-506.
64. Burgoyne CF, Downs JC. Premise and prediction-how optic nerve head biomechanics underlies the susceptibility and clinical behavior of the aged optic nerve head. J Glaucoma 2008; 17(4): 318-28.
65. Albon J, Karwatowski WS, Easty DL, Sims TJ, Duance VC. Age related changes in the non-collagenous components of the extracellular matrix of the human lamina cribrosa. Br J Ophthal 2000; 84(3): 311-7.
66. Morrison JC, Jerdan JA, Dorman ME, Quigley HA. Structural proteins of the neonatal and adult lamina cribrosa. Arch Ophthalmol 1989; 107(8): 1220-4.
67. Pena JD, Roy S, Hernandez MR. Tropoelastin gene expression in optic nerve heads of normal and glaucomatous subjects. Matrix Biol 1996; 15(5): 323-30.
68. Quigley HA. Childhood glaucoma: results with trabeculotomy and study of reversible cupping. Ophthalmology 1982; 89(3): 219-26.
69. Albon J, Farrant S, Akhtar S, Young R, Boulton ME, Smith G, et al. Connective tissue structure of the tree shrew optic nerve and associated ageing changes. Invest Ophthalmol Vis Sci 2007; 48(5): 2134-44.
70. Albon J, Purslow PP, Karwatowski WS, Easty DL. Age related compliance of the lamina cribrosa in human eyes. Br J Ophthal 2000; 84(3): 318-23.
71. Hernandez MR, Luo XX, Andrzejewska W, Neufeld AH. Agerelated changes in the extracellular matrix of the human optic nerve head. Am J Ophthalmol 1989; 107(5): 476-84.
72. Kotecha A, Izadi S, Jeffery G. Age-related changes in the thickness of the human lamina cribrosa. Br J Ophthalmol 2006; 90(12): 1531-4.
73. Albon J, Karwatowski WS, Avery N, Easty DL, Duance VC. Changes in the collagenous matrix of the aging human lamina cribrosa. Br J Ophthalmol 1995; 79(4): 368-75.
74. Brown CT, Vural M, Johnson M, Trinkaus-Randall V. Age-related changes of scleral hydration and sulfated glycosaminoglycans. Mech Ageing Dev 1994; 77(2): 97-107.
75. Bailey AJ, Paul RG, Knott L. Mechanisms of maturation and ageing of collagen. Mech Ageing Dev 1998; 106(1-2): 1-56.
76. Grunwald JE, Piltz J, Patel N, Bose S, Riva CE. Effect of aging on retinal macular microcirculation: a blue field simulation study. Invest Ophthalmol Vis Sci 1993; 34(13): 3609-13.
77. Harris A, Harris M, Biller J, Garzozi H, Zarfty D, Ciulla TA, et al. Aging affects the retrobulbar circulation differently in women and men. Arch Ophthalmol 2000; 118(8): 1076-80.
78. Hernandez MR, Wang N, Hanley NM, Neufeld AH. Localization of collagen types I and IV mRNAs in human optic nerve head by in situ hybridization. Invest Ophthalmol Vis Sci 1991; 32(8): 2169-77.
79. Shoulson I. Experimental therapeutics of neurodegenerative disorders: unmet needs. Science 1998; 282(5391): 1072-4.
80. Sena DF, Ramchand K, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2010; 2(2): CD006539.
81. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009; 87(4): 450-4.
82. Novack GD, O'Donnell MJ, Molloy DW. New glaucoma medications in the geriatric population: efficacy and safety. J Am Geriatr Soc 2002; 50(5): 956-62.
83. Zeevalk GD, Nicklas WJ. Evidence that the loss of the voltagedependent Mg2+ block at the N-methyl-D-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism. J Neurochem 1992; 59(4): 1211-20.
84. Nucci C, Tartaglione R, Rombolà L, Morrone LA, Fazzi E, Bagetta G. Neurochemical evidence to implicate elevated glutamate in the mechanisms of high intraocular pressure (IOP)-induced retinal ganglion cell death in rat. Neurotoxicology 2005; 26(5): 935-41.
85. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 1996; 114(3): 299-305.
86. Gu Z, Yamamoto T, Kawase C, Matsubara M, Kawase K, Sawada A, et al. Neuroprotective effect of N-methyl-D-aspartate receptor antagonists in an experimental glaucoma model in the rat. Nippon Ganka Gakkai Zasshi 2000; 104(1): 11-6.
87. WoldeMussie E, Yoles E, Schwartz M, Ruiz G, Wheeler LA. Neuroprotective effect of memantine in different retinal injury models in rats. J Glaucoma 2002; 11(6): 474.
88. Vorwerk C, Lipton S, Zurakowski D, Hyman B, Sabel B, Dreyer E. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci 1996; 37(8): 1618.
89. Lagreze W, Knorle R, Bach M, Feuerstein T. Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest Ophthalmol Vis Sci 1998; 39(6): 1063.
90. Osborne NN. Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia. Vis Neurosci 1999; 16(01): 45-52.
91. Hare W A, Wheeler L. Experimental glutamatergic excitotoxicity in rabbit retinal ganglion cells: block by memantine. Invest Ophthalmol Vis Sci 2009; 50(6): 2940-8.
92. Yücel YH, Gupta N, Zhang Q, Mizisin AP, Kalichman MW, Weinreb RN. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthalmol 2006; 124(2): 217-25.
93. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988; 451(1-2): 205-12.
94. Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol 1957; 58(2): 193-201.
95. Kanki R, Nakamizo T, Yamashita H, Kihara T, Sawada H, Uemura K, et al. Effects of mitochondrial dysfunction on glutamate receptor- mediated neurotoxicity in cultured rat spinal motor neurons. Brain Res 2004; 1015(1-2): 73-81.
96. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 1999; 81(3): 163-221.
97. Estevez AG, Stutzmann JM, Barbeito L. Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron- enriched cultures. Eur J Ophthalmol 1995; 280(1): 47-53.
98. Rego AC, Oliveira CR. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem Res 2003; 28(10): 1563-74.
99. Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A, et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA 2007; 104(33): 13444-9.
100. Tamura H, Kawakami H, Kanamoto T, Kato T, Yokoyama T, Sasaki K, et al. High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. J Neurol Sci 2006; 246(1-2): 79-83.
101. Wostyn P. Can chronic increased intracranial pressure or exposure to repetitive intermittent intracranial pressure elevations raise your risk for Alzheimer's disease? Med Hypotheses 2004; 62(6): 925-30.
102. Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur Neurol 2002; 47(3): 165-8.
103. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer's disease. N Engl J Med 1986; 315(8): 485-7.
104. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, Merges CA, Pease ME, Kerrigan DF, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci 2002; 43(4): 1077-87.
105. Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 2001; 414(6864): 643-8.
106. Kamal A, Stokin GB, Yang Z, Xia CH, Goldstein LS. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 2000; 28(2): 449-59.
107. Pigino G, Morfini G, Pelsman A, Mattson MP, Brady ST, Busciglio J. Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci 2003; 23(11): 4499-508.
108. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48(3): 626-32.
109. Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci 2000; 41(13): 4169.
110. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res 2006; 25(5): 490-513.
111. Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res 2004; 23(1): 53-89.
112. Tatton WG, Olanow CW. Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochim Biophys Acta 1999; 1410(2): 195-213.
113. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res 1999; 18(1): 39-57.
114. Kipnis J, Yoles E, Schori H, Hauben E, Shaked I, Schwartz M. Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J Neurosci 2001; 21(13): 4564.
115. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, Sela M, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci USA 2000; 97(13): 7446-51.
116. Bakalash S, Kessler A, Mizrahi T, Nussenblatt R, Schwartz M. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Invest Ophthalmol Vis Sci 2003; 44(8): 3374-81.
117. Yoles E, Hauben E, Palgi O, Agranov E, Gothilf A, Cohen A, et al. Protective autoimmunity is a physiological response to CNS trauma. J Neurosci 2001; 21(11): 3740.
118. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999; 5(1): 49-55.
119. Schori H, Kipnis J, Yoles E, WoldeMussie E, Ruiz G, Wheeler LA, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci USA 2001; 98(6): 3398-403.
120. Schori H, Yoles E, Schwartz M. T-cell-based immunity counteracts the potential toxicity of glutamate in the central nervous system. J Neuroimmunol 2001; 119(2): 199-204.
121. Avidan H, Kipnis J, Butovsky O, Caspi RR, Schwartz M. Vaccination with autoantigen protects against aggregated beta-amyloid and glutamate toxicity by controlling microglia: effect of CD4+CD25+ T cells. Eur J Ophthalmol 2004; 34(12): 3434-45.
122. Kipnis J, Schwartz M. Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. Trends Mol Med 2002; 8(7): 319-23.
123. Barron MJ, Griffiths P, Turnbull DM, Bates D, Nichols P. The distributions of mitochondria and sodium channels reflect the specific energy requirements and conduction properties of the human optic nerve head. Br J Ophthalmol 2004; 88(2): 286-90.
124. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6(5): 513-9.
125. Korsmeyer SJ, Yin XM, Oltvai ZN, Veis-Novack DJ, Linette GP. Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Biochim Biophys Acta 1995; 1271(1): 63-6.
126. Ravagnan L, Roumier T, Kroemer G. Mitochondria, the killer organelles and their weapons. J Cell Physiol 2002; 192(2): 131-7.
127. Ju W-K, Liu Q, Kim K-Y, Crowston JG, Lindsey JD, Agarwal N, et al. Elevated hydrostatic pressure triggers mitochondrial fission and decreases cellular ATP in differentiated RGC-5 cells. Invest Ophthalmol Vis Sci 2007; 48(5): 2145-51.
128. Abu-Amero KK, Morales J, Bosley TM. Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2006; 47(6): 2533-41.
129. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004; 429(6990): 417-23.
130. Anandatheerthavarada HK, Biswas G, Robin M-A, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 2003; 161(1): 41-54.
131. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001; 21(9): 3017-23.
132. Casley CS, Land JM, Sharpe MA, Clark JB, Duchen MR, Canevari L. Beta-amyloid fragment 25-35 causes mitochondrial dysfunction in primary cortical neurons. Neurobiol Dis 2002; 10(3): 258-67.
133. Zini R, Morin C, Bertelli A, Bertelli AAE, Tillement J-P. Resveratrol-induced limitation of dysfunction of mitochondria isolated from rat brain in an anoxia-reoxygenation model. Life Sci 2002; 71(26): 3091-108.
134. Sanz A, Caro P, Ibañez J, Gómez J, Gredilla R, Barja G. Dietary restriction at old age lowers mitochondrial oxygen radical production and leak at complex I and oxidative DNA damage in rat brain. J Bioenerg Biomembr 2005; 37(2): 83-90.
135. Merry BJ. Oxidative stress and mitochondrial function with aging-- the effects of calorie restriction. Aging Cell 2004; 3(1): 7-12.
136. Anson RM, Guo Z, Cabo R de, Iyun T, Rios M, Hagepanos A, et al. Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. Proc Natl Acad Sci USA 2003; 100(10): 6216-20.
137. Gredilla R, Sanz A, Lopez-Torres M, Barja G. Caloric restriction decreases mitochondrial free radical generation at complex I and lowers oxidative damage to mitochondrial DNA in the rat heart. FASEB J 2001; 15(9): 1589-91.